Insider trade

Officer sold ~$83K of EW shares in the open market

Traded Apr 6, 2026 · Filed Apr 7, 2026

~$83K
Approx. value · 1,019 sh @ $80.98: 34K
Holds after · shares reported: +7.4%
stock since the trade · S&P 500 +17.6%, $81.19 → $87.23 on Oct 5

Why it stands out

Edwards Lifesciences's CVP, TAVR sold $83K of Edwards Lifesciences shares. The filing says it was made under a pre-arranged trading plan.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Apr 6, 2026
Reporting period: Not applicable
Filed with the SEC: Apr 7, 2026

Officer$25K–$100KPre-arranged plan referenced

Context

Classification

open market sale

Code S — open-market or private sale

Absolute commitment

~$82,523

Shares × reported transaction price

Timing vs results

55 days after results of Feb 10, 2026, 17 days before results of Apr 23, 2026

Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results

Price at the time

Closed at $81.19 on Apr 6, 2026, 21% above its 52-week low and 7% below its high, after a 2% rise over the previous 30 trading days

52-week range $67.07 (Apr 8, 2025) to $87.18 (Mar 2, 2026), 70% of the way up, from 250 adjusted closes. 30 trading days earlier: $79.78 on Feb 20, 2026. Describes the past only, not a forecast

Planned / mechanical clue

Footnote references a pre-arranged trading plan (Rule 10b5-1)

Only flagged when a footnote says so; never inferred

Securities lawsuit open at the trade date

A securities lawsuit naming the company as a defendant was filed on Oct 14, 2024 in the U.S. District Court, C.D. California. A filing is an allegation, not a finding.

Dhimant Patel v. Edwards Lifesciences Corporation, docket 8:24-cv-02221, via CourtListener (court records). Nature of suit 850, company named as first defendant

After it was reported

After	Stock	S&P 500	Difference
7 days	−3.3%	+5.3%	−8.6%
30 days	+2.4%	+11.0%	−8.6%
90 days	+17.7%	+14.0%	+3.8%
180 days	+7.9%	+17.5%	−9.6%

Past results only. Not a forecast.

Source receipt

Record ID: 0001225208-26-004422
Filed / recorded: Apr 7, 2026, 12:42 AM UTC
Added to OQRO: Oct 2, 2026, 12:27 PM UTC
Parser: form4-xml-v1
Data quality: Verified: identifiers matched exactly
Issuer: Edwards Lifesciences Corp
Issuer CIK: 1099800
Ticker: EW
Reporting person: Daniel J. Lippis
Relationship: Officer
Officer title: CVP, TAVR
Security: Common Stock
Table: Non-derivative (Table I)
Transaction date: Apr 6, 2026
Transaction code: S
Shares / units: 1,019
Price per share: $80.98
Acquired / disposed: Disposed (D)
Shares owned after: 33,933.9103
Ownership form: Direct
Amendment: No

Footnotes from the filing

The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on July 30, 2025.
This transaction was executed in multiple trades at prices ranging from $80.64 to $81.07. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, upon request by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.